Abstract 311P
Background
Thyroid cancer is the most common endocrine-related malignancy in the Philippines. It ranks seventh overall based on the latest Department of Health statistics. Its incidence increases every year, noted especially in females and in the reproductive age group. This study determined the incidence and the profile of all thyroid carcinomas encountered in a tertiary teaching hospital in the Philippines.
Methods
Data were collected from the University of Santo Tomas Hospital in 2015 to 2018 from different specialties, including the Pathology Department. All information gathered were kept confidential in respect to the data privacy act.
Results
A total of 1618 thyroid specimens were sent for histopathologic examination from 2015-2018 and 35.6% (n = 576) of these were malignant. Fine needle aspiration was the most frequent form of biopsy done. Eight hundred eighty patients underwent thyroidectomy and 43% (n = 378) of them had malignancy based on final histopathology. Eighty one percent (81%) were females and 19% were males. The most common type of malignancy was papillary thyroid carcinoma (74.6%), followed by papillary microcarcinoma (18.4%), follicular carcinoma (4.8%), anaplastic carcinoma (0.7%), squamous cell (0.7%) and poorly differentiated carcinoma (0.9%). The most frequent subtype of papillary carcinoma seen was the conventional type (31.7%). Majority of the patients had no extrathyroidal extension (41%), no lymphovascular invasion (38%), had clear margins (70%) and had no lymph node involvement (21%). Of the patients diagnosed with papillary and follicular carcinoma and papillary microcarcinoma, 30% underwent RAI in the same institution. There were 17 patients who underwent radiation therapy, mostly for palliative intent because of RAI-refractory disease. There was one case who underwent concurrent chemoradiation for anaplastic thyroid carcinoma.
Conclusions
This study showed that one-third of thyroid specimens received in the institution turned out to be malignant, with papillary carcinoma still the most frequent type. Total thyroidectomy is the most common form of curative surgery done.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
490P - Outcomes of sequential epidermal growth factor receptor tyrosine (EGFR) tyrosine kinase inhibitor (TKI) therapy in patients with advanced non-small cell lung carcinoma (NSCLC)- a real-world institutional experience
Presenter: Yvonne Ang
Session: Poster display session
Resources:
Abstract
498P - An observational retrospective study to evaluate the incidence of acquired EGFR T790M resistance in NSCLC patients with EGFR mutation following progression after at least one prior EGFR TKI treatment in Taiwan: ARISE study
Presenter: Shang-gin Wu
Session: Poster display session
Resources:
Abstract
501P - Clinical characteristics and efficacy in non-small cell lung cancer patients with EGFR exon 20 insertion and EGFR amplification
Presenter: Xin Gao
Session: Poster display session
Resources:
Abstract
502P - Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced non-small cell lung cancer with uncommon mutations: A multicenter observational study
Presenter: Masaki Kanazu
Session: Poster display session
Resources:
Abstract
482P - Interim analysis from a phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC
Presenter: Filippo De Marinis
Session: Poster display session
Resources:
Abstract
483P - A phase IIIb, open-label study of afatinib in EGFR TKI-naïve patients with EGFR mutation-positive NSCLC: A biomarker analysis
Presenter: Rafael Rosell
Session: Poster display session
Resources:
Abstract
484P - Activity of afatinib in patients (pts) with EGFR mutation-positive (EGFRm+) NSCLC and baseline brain metastases: Pooled analysis of three large phase IIIb trials
Presenter: Maya Gottfried
Session: Poster display session
Resources:
Abstract
491P - Clinical outcomes of leptomeningeal metastases in EGFR-mutant lung adenocarcinoma
Presenter: Chia-I Shen
Session: Poster display session
Resources:
Abstract
510P - Paclitaxel as continuation maintenance therapy in patients with advanced non-small cell lung cancer
Presenter: Suzy Gohar
Session: Poster display session
Resources:
Abstract
496P - Higher osimertinib introduction rate achieved by multiple repeated re-biopsy after acquired resistance to first/second generation EGFR-TKIs
Presenter: Taira Ninomaru
Session: Poster display session
Resources:
Abstract